TP53 and intrahepatic cholangiocarcinoma: Similarly, the ICC defines TP53-mutated MDS based on the presence of two mutations with a VAF > 10%, or one mutation associated with a complex karyotype (typically involving 17p-), VAF > 50%, or cnLOH, in patients with bone marrow blasts below 10%.